Biology Atlas

Map / Organisations

organisation · intermediate · partly written

BenevolentAI

BenevolentAI is a company whose proprietary biomedical knowledge graph flagged baricitinib for 2019-nCoV in a company-authored letter.

What it claimed, and what is its own claim more

The Lancet letter, whose authors apart from one are company employees, reports that of 378 AAK1 inhibitors in the graph, 47 were approved and six had high affinity, with baricitinib the only non-oncology one, and says it is not medical advice. This is the company's claim about its own graph and it was not independently tested here. Whether a literature search would have found baricitinib is untested. 1

Reported, not yet replicated

Offers

Knowledge-graph target and repurposing hypotheses

Proprietary graph used to propose drugs for repurposing; documented here only through one company-authored letter. 1

Reported, not yet replicated

Caveats

Company claims about its own graph are not independently tested; no vendor documentation was opened. 1

Reported, not yet replicated

Still open here

Not yet written: URL.

Linked from

Sources

  1. Richardson P, et al.. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet (2020). paper; opened 2026-11-18 all records citing this
Where it sits on the map
History of this record (5)

This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Kind
company
Status
partly written
Last updated
2026-11-19
Record
content/organisations/benevolentai.json